Iovance Biotherapeutics, Inc. (IOVA)
Nasdaq: IOVA · Biological Products, (No Diagnostic Substances) · San Carlos, CA · filing with the SEC since 2008
Who owns Iovance Biotherapeutics, Inc.
As filed with the SECHolders of 5% or more
2
Blackrock, Inc. holds 7.5% of Common Stock, as its SCHEDULE 13G/A filed Jul 28, 2026 says.
Directors and officers
11
report now, of 29 people on the record since 2011. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 28, 2026 · Common Stock · 6.4% in Jul 17, 2025
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK · 4.2% in May 12, 2026
Perceptive Advisors LLC
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.000041666 per share · reported falling below 5%, from 7.3% in Feb 14, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 7.5% in Jul 29, 2025
What IOVA reports owning in othersstakes of 5% or more, and other ties
6 subsidiaries in 5 countries, from the list filed with the 10-K filed Feb 27, 2025.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.